HK Stock Market Move | LAEKNA-B(02105) increased by more than 15% again, with a total increase of more than 40% within the month. LAE002 recently won a large order from BD.

LAEKNA-B (02105) rose more than 15%, with a cumulative increase of over 40% in the month. As of press time, it rose by 15.38% to HK$16.95, with a turnover of HK$58.2171 million. On the news front, on November 12, Laikna Pharmaceutical granted the regional rights of the breast cancer candidate drug, LAE002 (afuresertib), to Qilu Pharmaceutical in China for a total transaction amount of 2.045 billion yuan. Laikna Pharmaceutical also has the right to receive tens to over a hundred points of sales royalties. According to brokerage research reports, the domestic sales peak of LAE002 is estimated to be around 2 billion yuan, and the global sales peak can be referenced to Capivasertib. Capivasertib's sales expectations for this year are 700-800 million US dollars, with sales peak estimated to be 1-2 billion US dollars.